Last reviewed · How we verify
B2:SG
At a glance
| Generic name | B2:SG |
|---|---|
| Sponsor | Fudan University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors (PHASE1)
- An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- B2:SG CI brief — competitive landscape report
- B2:SG updates RSS · CI watch RSS
- Fudan University portfolio CI